Ultrasound contrast agents
This article was originally published in The Gray Sheet
Executive Summary
Imavist contrast agent, developed jointly by Alliance Pharmaceutical and Schering AG, will enter a favorable reimbursement environment following FDA approval, the firms note. In July, CMS created new APCs defining ultrasound contrast agents as drugs and making them eligible for outpatient prospective "pass-through" payments covering 95% of their average wholesale cost, Alliance explains. The company has submitted the documentation requested by FDA in its August 2000 "approvable" letter and expects to launch the product by year-end